Home › Trials › NCT06516406

Observational study on ruxolitinib for myelofibrosis patients

Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera

Observational IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06516406

This study looks at how well ruxolitinib works for people with myelofibrosis and how different factors affect their long-term survival.

Quick facts

Study typeObservational
Enrollment1055 (estimated)
Ages18 Years and up
SexAll
SponsorIRCCS Azienda Ospedaliero-Universitaria di Bologna Academic / other
Drugs / interventionsruxolitinib
Locations26 sites (Cosenza, Calabria and 25 other locations)
Trial IDNCT06516406 on ClinicalTrials.gov

What this trial studies

This observational multicenter study examines patients with primary or secondary myelofibrosis who have started treatment with ruxolitinib as part of their standard care. It aims to assess how clinical and laboratory characteristics influence the long-term survival of these patients. Data will be collected retrospectively and prospectively, including systemic symptoms and splenomegaly assessments, over a minimum observation period of three months and a total study duration of ten years.

Who should consider this trial

Good fit: Ideal candidates include adults aged 18 and older diagnosed with primary myelofibrosis or secondary myelofibrosis related to essential thrombocythemia or polycythemia vera who are receiving ruxolitinib therapy.

Not a fit: Patients who are not receiving ruxolitinib or those with other forms of myelofibrosis not related to the specified conditions may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide insights into the prognosis of myelofibrosis patients treated with ruxolitinib, potentially improving patient management and outcomes.

How similar studies have performed: Other studies have shown promising results with ruxolitinib in treating myelofibrosis, indicating that this approach is supported by existing evidence.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Age ≥ 18 years
* Patients diagnosed with Primary Myelofibrosis or secondary to Essential Thrombocythemia/Polycythemia vera who are being treated or have been treated with ruxolitinib therapy in accordance with normal clinical practice.
* Availability of data on clinical history prior to initiation of Ruxolitinib therapy
* Obtaining informed consent for data collection and processing

Exclusion Criteria:

* None

Where this trial is running

Cosenza, Calabria and 25 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions MyelofibrosisPrimary MyelofibrosisSecondary MyelofibrosisSafetyEfficacy
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.